scholarly journals Treatment Patterns Among Medicaid-Eligible Women With Breast Cancer in Georgia: Are Patterns Different Under the Breast and Cervical Cancer Prevention and Treatment Act?

2012 ◽  
Vol 8 (1) ◽  
pp. 46-52 ◽  
Author(s):  
E. Kathleen Adams ◽  
Li-Nien Chien ◽  
Sheryl G.A. Gabram-Mendola

The Breast and Cervical Cancer Prevention and Treatment Act program in Georgia creates a quicker pathway for low-income, uninsured women with breast cancer to access services and receive more treatment than women enrolled in traditional Medicaid eligibility groups.

2010 ◽  
Vol 28 (21) ◽  
pp. 3479-3484 ◽  
Author(s):  
Jennifer L. Malin ◽  
Allison L. Diamant ◽  
Barbara Leake ◽  
Yihang Liu ◽  
Amardeep Thind ◽  
...  

Purpose The objective of this study was to evaluate the quality of care provided to uninsured women with breast cancer who received treatment through the Breast and Cervical Cancer Prevention Treatment Program (BCCTP). Methods Participants included women with stage I to III breast cancer (n = 658) from a consecutive sample of women 18 years or older who received coverage through the California BCCTP between February 2003 and September 2005 who consented to a survey and medical record review (61% response rate). Quality of breast cancer care was evaluated using 29 evidence-based quality measures developed for the National Initiative for Cancer Care Quality (NICCQ). NICCQ, a largely insured cohort of women diagnosed with stage I to III breast cancer in 1998, was used to benchmark the results. Results Twenty-three percent of women presented with stage III disease compared with fewer than 10% nationally. Patients received 93% of recommended care (95% CI, 92% to 93%). Adherence to recommended care within domains ranged from 87% for post-treatment surveillance (95% CI, 84% to 90%) to 97% for diagnostic evaluation (95% CI, 96% to 97%). Compared to the NICCQ cohort, adherence to quality measures was as good or better for the BCCPT cohort in all domains except post-treatment surveillance. Conclusion The BCCTP has made important inroads in providing poor, uninsured women with access to high quality care when faced with the diagnosis of breast cancer; however, many present at an advanced stage, which is associated with worse outcomes.


Cancer ◽  
2009 ◽  
Vol 115 (6) ◽  
pp. 1300-1309 ◽  
Author(s):  
E. Kathleen Adams ◽  
Li-Nien Chien ◽  
Curtis S. Florence ◽  
Cheryl Raskind-Hood

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 153-153
Author(s):  
E. K. Adams ◽  
S. G. A. Gabram ◽  
L. Chien

153 Background: The Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) of 2000 allowed states to cover women diagnosed with breast, cervical, or pre-cancerous cervical conditions under Medicaid upon diagnosis and while “under treatment”. We investigate breast cancer treatment of patients enrolled under BCCPTA in Georgia. Methods: Georgia Comprehensive Cancer Registry were linked to Medicaid enrollment files to identify 2,048 enrollees with a primary cancer of breast, of whom 1,046 were BCCPTA, 674 were disabled, and 328 were in ‘other’ Medicaid eligibility groups. Logistic regressions were used to estimate the odds of receiving: (1) lumpectomy, (2) mastectomy, and (3) other surgery in addition to (4) any drug regimen (hormonal or chemotherapy) and (5) radiation. Results: Using descriptive data and after controlling for covariates, BCCPTA women are more likely to receive any treatment (OR = 4.71, [CI] = 2.48, 8.96), any drug regimen (OR = 3.58, [CI] =2.32, 5.51), any radiation (OR = 1.61, [CI] = 1.15, 2.24), and any ‘definitive’ surgery (OR = 2.52, [CI] = 1.74, 3.66) than the ‘other’ eligibility group. There are no significant differences in the receipt of a lumpectomy versus a mastectomy by eligibility group but BCCPTA women are more likely to receive more adjuvant follow-up. Conclusions: The BCCPTA program in Georgia appears to create a quicker pathway for previously low-income uninsured women with breast cancer to access services and in turn, receive more treatment than women enrolled in more traditional, Medicaid eligibility groups. Yet, the overall rate of adjuvant therapy, whether radiation or hormonal/chemotherapy, appears to fall short of national criteria. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document